Colloquium
8:00 am–8:00 pm
A full day of lectures, platform sessions, case studies, panel discussions, and scientific posters.
Schedule is tentative and subject to change. Breakfast, lunch, and all talks will be held in Room 6A of the San Diego Convention Center.
Registration / Badge Pick-up
7:00 am – 10:30 am
Breakfast
7:30 am – 8:00 am
Opening Remarks
8:00 am – 8:10 am
Barbara Slusher, PhD, MAS – ADDC Founder and President
Small-Molecule Success Stories
8:10 am – 10:10 am
Chair: Stephen Frye – UNC Chapel Hill
Discovery of Aldas, Activators of Aldehyde Dehydrogenase from HTS to Startup
David E. Solow-Cordero, PhD – Stanford
Targeting Protein-protein Interactions for New Cancer Therapeutics
Shaomeng Wang, PhD – University of Michigan
NeurOp – Glutamatergic Receptor Pharmacology
Stephen F. Traynelis, PhD – Emory University
RPC1063 from NIH Library to Startup
Hugh Rosen, MD, PhD – The Scripps Research Institute Molecular Screening Center
Session sponsored by Adis Insight
Coffee Break
10:10 am – 10:30 am
Small-Molecule Success Stories and Emerging Opportunities
10:30 am – 12:05 pm
Chair: Marcie Glicksman – Harvard Medical School
Drug Discovery at a Small Academic Institution: The Story of 5HMF through Clinical Trials
Umesh R. Desai, PhD – Virginia Commonwealth University
Discovery and Characterization of Apelin Receptor Ligands as Therapeutics for Metabolic Syndrome
Rangan Maitra, PhD – RTI International
Cx3cr1 Chemokine Antagonists Halt Metastatic Spreading In Animal Models of Metastasis
Joseph M. Salvino, PhD – Drexel University College of Medicine
Towards an Efficacious, in vivo Protease Activated Receptor 4 Antagonist
Matthew T. Duvernay, PhD – Vanderbilt University
Session sponsored in part by Waters.
Lunch
12:05 pm – 1:10 pm
Sponsored by Millipore Sigma
Rare and Neglected Diseases
1:10 pm – 2:55 pm
Chair: Michael Wood, PhD – AstraZeneca Pharmaceuticals LP
Keynote: The Landscape of R&D Opportunities to Improve Health Conditions in Developing Countries
R. Michael Poole, MD FACP – Gates Foundation
Structure-Guided Drug Discovery Consortium (SDDC)
Aled Edwards, PhD – University of Toronto
Advancing Translational Research for Tau Pathologies
Bruce L. Miller, MD – Tau Consortium
Rapid Isolation and Development of Human Antiviral Neutralizing Monoclonal Antibodies
James E. Crowe Jr, MD – Vanderbilt University
Coffee Break
2:55 pm – 3:15 pm
Government Funding Opportunities to Advance Drug Discovery
3:15 pm – 3:50pm
Chair: Barbara Slusher, PhD, MAS – Johns Hopkins Univ. Brain Science Institute
NCI Chemical Biology Consortium/NExt Program
Barbara Mroczkowski – National Cancer Institute / NIH
NIH Blueprint Program
Amir Tamiz, PhD – NIH Blueprint Program
Panel Session: Advancing and Partnering Drug Discovery Programs
3:55 pm – 4:40 pm
Chair: Michelle Arkin – Univ. of California, San Francisco
Panelists: Barbara Mroczkowski, Amir Tamiz, Mike Poole, Shaomeng Wang, Hugh Rosen, Michael Wood
Session sponsored in part by CDD Vault.
Wrap-up
4:40 pm – 4:50 pm
Poster Session / Dinner Reception
5:30 pm - 8:00 pm
Room 5AB
Individual Partnering Meetings
Marriott Marquis San Diego Marina
2:00 pm – 8:00 pm
Colloquium speakers and attendees from academia and drug discovery centers will be taking appointments with other registered colloquium participants. Once you register for the meeting you will be sent a link to sign-up for appointments. The appointments will all take place in one room at separate tables.
Participants Accepting Appointments
Tentative list as of 3/23/2016
- Alabama Drug Discovery Alliance, Alabama Drug Discovery Alliance (ADDA), Antiviral Drug Discovery and Development Center (AD3C), Univ. of Alabama at Birmingham
- Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy
- CINVESTAV
- Drexel University
- GridRepublic
- Johns Hopkins University Drug Discovery
- Johns Hopkins University School of Medicine, The Neurofibromatosis Therapeutic Acceleration Program
- Michigan State University
- National Institute of Neurological Disorders and Stroke (NINDS) / NIH
- RTI International
- Stanford University
- The Scripps Research Institute
- University of California CTSI Catalyst Program
- University of California, San Francisco
- University of Kentucky
- University of South Florida, Center for Drug Discovery and Innovation
- University of Toronto
- Vanderbilt University
- Virginia Commonwealth University
More Information on Participants
The ADDA is a cooperative effort between UAB and Southern Research. By combining the expertise and capabilities of each organization, the ADDA can focus on novel targets and mechanisms, efficiently moving programs from target validation through pre-clinical development. Our current efforts are focused in the areas of CNS, Oncology and Metabolic Diseases. We are actively looking for commercial partners to help us move our programs forward, and we are very flexible in how we can structure relationships with potential partners.
Programs in AD, PD, B-Cell Malignancies, Multiple Myeloma, Tuberculosis, and others.
Highlighted programs: Tau-Fyn inhibitors for AD, 14-3-3 proteins for PD, TGF(beta) for multiple myeloma.
Therapeutic Approaches: Small Molecules, Biomarkers
Therapeutic Areas of Expertise: Neurological Disorders, Oncology, Pain
A detail sheet from Kerberos Biopharmaceutical Inc. related to Dr. Joseph Salvino’s presentation “Cx3cr1 Chemokine Antagonists Halt Metastatic Spreading In Animal Models of Metastasis” is available on request.
Grid Republic provides low-cost tools and services for high-performance bioinformatics through shared distributed computing. We have clocked over 88 million CPU years towards programs and function (on a distributed basis) as one of the world’s largest supercomputers (as measured by teraflops).
Grid Republic uses distributed computing (i.e., SETI@home style) to drive its services and provides:
- Fast and cheap high-throughput screening and optimization, using a hybrid of computational and laboratory methods.
- Tools and services to power research with massively large scale genomics datasets (e.g. BLAST-search the full Sequence Read Archive)
JHDD is seeking companies interested in partnering broadly with the Academic Drug Discovery Colloquium.
JHDD is also seeking partner companies interested in partnering specifically with JHDD on a variety of programs, including in Oncology, Autoimmune Disease, GI/IBD, NeuroAIDs, Brain Cancer, Peripheral Neuropathy, Pain, and Schizophrenia
Highlighted program: Development of Glutamine Antagonist Prodrugs for treating Cancer and Immune Disorders
Based at Johns Hopkins University, The Neurofibromatosis Therapeutic Acceleration Program (NTAP) was founded in 2012 as a research enterprise which focuses on developing therapeutics for a rare, incurable and debilitating tumor, plexiform neurofibromas (pNF). pNF are nerve sheath tumors that afflict patients with the genetic syndrome Neurofibromatosis Type 1 (NF1).
NTAP is focused on developing treatments to plexiform Neurofibromatosis (pNF). However, pNF has overlapping mechanisms with links to cancer, inflammation, allergy, dermatology, and stress/repair contributing to the disease pathogenesis.
NTAP mission objectives:
- Develop both broad and deep collaborations (e.g., Children’s Tumor Foundation)
- Identify and efficiently fill critical knowledge gaps
- Timely and open sharing of results
NTAP is keen to establish relationships with partners who may have compounds, platforms, or technologies, that could be beneficial for the treatment of plexiform neurofibromas (pNF). Director of R&D for NTAP: Dr. Sharad K. Verma (sverma20@jhmi.edu).
RTI International
RTI is looking to develop partnerships around:
- Cardiovascular diseases, particularly heart failure
- Pulmonary hypertension
- Metabolic diseases
- Steatohepatitis
Therapeutic Approaches: Biologics, Small Molecules
Therapeutic Areas of Expertise: Cardiology, Immunology, Infectious Diseases, Neurological Disorders, Oncology, Regenerative Medicine
Therapeutic Approaches: Small Molecules, Antibodies
Therapeutic Areas of Expertise: Immunology, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology
Ongoing projects in Oncology, Neurodegenerative Disease, and the linkages between these diseases. In addition, our Center is focused on developing technologies for challenging targets such as protein-protein interactions, allosteric sites, and proteases, using multiple technologies such as fragment-based lead discovery (including the Tethering/disulfide-trapping technology). Our lead programs include allosteric inhibitors of p97/VCP for cancer/aging and novel inhibitors of proteases involved in cancer and Alzheimer ’s disease.
The Vanderbilt High-Throughput Screening (HTS) facility provides screening-based services to aid research investigators in the identification and investigation of new compounds for pharmacological discovery and basic research. The facility provides services to both internal (Vanderbilt) and external academic and industry customers. Resources and capabilities includes the availability of targeted and diverse small molecule libraries totaling over 350,000, 2 kinetic imaging plate readers, 2 multimode plate readers (absorbance, fluorescence, luminescence, Alpha, TRF, FP), high-content imaging (Molecular Devices ImageXpress Micro XL), and acoustic and tip-based liquid handling platforms.
Vanderbilt University – PAR4 research program. (Dr. Duvernay)
Interested in partnering with labs that have established:
- higher order primate models of in vivo thrombosis and
- models for diseases that PAR4 has been implicated in by aberrant expression and knockout studies. These include: colon cancer, lung cancer, arthritis, sepsis, ischemia-reperfusion injury (cerebral or coronary), and irritable bowel disease to name a few.
Therapeutic Approaches: Small Molecules
Therapeutic Areas of Expertise: Infectious Diseases, Oncology, Regenerative Medicine
Therapeutic Approaches: Biologics, Small Molecules, Vaccines, Antibodies
Therapeutic Areas of Expertise: Cardiology, Immunology, Infectious Diseases, Metabolic Disorders, Neurological Disorders, Oncology, Psychiatric Disorders
Highlighted projects:
- Novel small molecule antifibrotics targeting the MRTF/SRF gene transcription pathway. In vivo efficacy published for bleomycin skin fibrosis and pulmonary fibrosis (bleo and genetic model). Publications are available online (PMID: 24740541 24706986 25681733).
- RGS4 inhibitors (PMID: 22368763, 25844489) for amelioration of Parkinson’s symptoms (PMID: 22284188, 25844489) and possibly dyskinesia (PMID: 24969021, 26590347).
The Institute for Structural Biology, Drug Discovery and Development (ISB3D) at VCU is focused on the interface of chemistry and biology. The ISB3D emphasis is structural biology, medicinal chemistry, molecular medicine, biotechnology, nanotechnology, metabolism, metabolomics, drug development, drug delivery and pharmaceutical manufacturing. The key disease areas that Institute focuses on include cancer and related diseases, blood and cardiovascular diseases, cognitive diseases and microbial (viral and bacterial) diseases.
The molecules being developed as drugs include the following:
- Venous and arterial thrombosis related disorders: SPGG, SCI, SMI and SG-09 as selective factor XIa targeting anticoagulants
- Cancer: G2.2 and its analogs as anti-cancer stem cells for colorectal, pancreatic and breast cancers; NT-7-16 as microtubule destabilizer for obviating taxol resistance; atricyclic platinum complex as anti-metastasis agent for breast, colon and pancreatic cancers
- Emphysema and related disorders: CDSO3 as modulator of HIF-1alpha for reversing (i.e., curing) the disease
- Influenza: PHE as M1 layer disruptor for treating multiple influenza strains
- Alzheimer’s disease: an orally available small molecule for treating Alzheimer’s disease
- Opioid-induced constipation: NAP, MNAP, NMP and MNMP as mu opioid receptor selective agents
The molecules described above have been selected following rigorous evaluation of multiple compounds and have shown major promise in appropriate animal model studies. Each of these technologies have unique innovator space that affords major advantage(s) over current therapeutics. Further, the intellectual property related to these technologies have priority dates of less than three years and thereby the technologies have a long operational life (~17 yrs). The technologies are available for licensing from VCU’s Innovation Gateway, a technology transfer hub (Dr. Ivelina Metchva, Director; Ph (804) 828-5188; ismetche@vcu.edu; Professor Umesh Desai is Director of (Ph. (804) 828 7328; urdesai@vcu.edu).
University of Toronto
Dr. Aled Edwards of the University of Toronto is presenting on the Structure‐Guided Drug Discovery Consortium (SDDC).
The SDDC Mission & Objectives include:
- Contributing to global discovery pipeline in tuberculosis and maliaria drug discovery by delivering early leads to Product Development Partnership (PDP) organisations the Medicines for Malaria Venture and the Global Alliance for TB Drug Development.
- Identifying and developing chemical assets (Early Leads and novel chemotypes) for High value targets for treating Tuberculosis and Malaria.
National Institute of Neurological Disorders and Stroke (NINDS) / NIH
Amir Tamiz, PhD of NINDS will be presenting on the NIH Blueprint Program.
The NIH Blueprint Program for Neuroscience Research has aimed to accelerate the pace of discovery in neuroscience research, and it generated many successful initiatives, programs, and resources to benefit the entire neuroscience community seek input from the scientific community for how best to continue to support research on the brain and nervous system.
Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy
The Center for Integrative Chemical Biology and Drug Discovery was created with the mission of bringing dedicated medicinal chemistry expertise to bear on biological targets of therapeutic relevance under investigation by UNC faculty. Synthetic chemists, assay development, and compound-profiling scientists work in the center and create dedicated, multidisciplinary project teams with other groups on campus in order to progress targets through the drug discovery and development process. The center provides leadership of the North Carolina Comprehensive Chemical Biology Center, a member of NCI’s Chemical Biology Consortium.
The Scripps Research Institute - Florida
The Scripps Research Institute (TSRI) — one of the world's largest, private, non-profit research organizations — stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers.
CIMA (El Centro de Investigación Médica Aplicada at Universidad de Navarra
CIMA has a number of pipeline products in Cancer, AD, HD, Heart Failure, Onco-immunology, and others. A pipeline PDF is available on request.
CINVESTAV
Pharmabiology Department
CINVESTAV is an academic institution belonging to the Mexican Government. Dr. Hong has found a few molecules with pharmacologycal activity that may be useful in metabolic syndrome or diabetes T2. He will also be presenting a poster about indorenate, a serotonin analogue.
University of California CTSI Catalyst Program
The UCSF Catalyst program is an innovative technology translation mechanism, which supports the development of therapeutics, devices, diagnostics and digital health applications from academic research. Researchers with promising technologies are mentored by expertise matched industry experienced advisors through the translation process. We have supported 50 therapeutics programs over the last 6 years. These range from small molecules and biologicals for the treatment of indications ranging from Cataracts to Cancer, Respiratory disease, Cardiovascular disease, Infection, CNS, Allergy, Hematology, Oncology, Imaging and delivery technologies. Catalyst works with partners from industry and academia to develop the projects and move them towards Clinical Proof of Concept and commercialization.